Transplantation After Complete Response In Patients With T-cell Lymphoma

Inclusion Criteria:

1. Patient ≥ 18 years and < 70 years of age at the time of signing the informed consentform (ICF)
2. Patient fit enough to receive autologous stem cell transplant as a consolidationstrategy as assessed by the local investigator
3. Hemoglobin level > 8g/dL (transfusion allowed); Neutrophil count >0.5 G/L; Plateletscount > 50 G/L (transfusion allowed) Patient with histologically proven "nodal-typeperipheral T-cell lymphoma (PTCL)" (latest WHO classification), not previouslytreated; as defined by the WHO classification, the following subtypes may be included,

• PTCL, not otherwise specified
• Follicular helper T-cell lymphomas: Angioimmunoblastic T-cell lymphoma and nodalPTCL with TFH phenotype and follicular T-cell lymphoma
• Anaplastic large cell lymphoma, ALK-negative

4. Ann Arbor staging (I-IV) except stage I with normal LDH and PS<2 (i.e. stage I aaIPI

5. Participant with a measurable disease by the Lugano criteria (i.e., longest diameterof a nodal site > 1.5 cm and/or longest diameter of an extranodal site > 1.0 cm and/ora hypermetabolic lesion)
6. FFPE Diagnostic tissue block should be available for central pathology review andancillary molecular analyses
7. Participant with Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
8. Estimated minimum life expectancy of 3 months
9. Patient who understood and voluntarily signed and dated an informed consent prior toany study-specific assessments/procedures being conducted
10. Able to adhere to the study visit schedule and other protocol requirements
11. Patient covered by any social security system (France)
12. Patient who understands and speaks one of the country official languages
13. Males with partners of childbearing potential must agree to use effective birthcontrol methods during the study as informed by the investigator in accordance withSmPC of each drugs administrated
14. Females of childbearing potential must agree to use effective birth control methodsfor at least 28 days before starting treatment; while participating in the study;during treatment interruptions and necessary period after the study as informed by theinvestigator in accordance with SmPC of each drugs administrated

Exclusion Criteria:

1. Known central nervous system or meningeal involvement by lymphoma
2. Impaired renal function (calculated MDRD or Cockcroft-Gault Creatinine Clearance < 30ml/min) or impaired liver function tests (serum total bilirubin level > 2.0 mg/dl [34 µmol/L] (except in case of Gilbert's Syndrome, or documented liver or pancreaticinvolvement by lymphoma), serum transaminases (AST or ALT) > 3 upper normal limitunless they are related to the lymphoma.
3. The following types of T-cell lymphomas:

• Adult T-cell lymphoma/leukemia (HTLV-1 related T-cell lymphoma)
• Extranodal T-cell/NK-cell lymphoma, nasal type
• Anaplastic large cell lymphoma, ALK-positive type
• Cutaneous T cell lymphoma (mycosis fungoides, Sézary syndrome)
• Primary cutaneous CD30+ T-cell lymphoproliferative disorder
• Primary cutaneous anaplastic T-cell lymphoma
• Enteropathy-associated T-cell lymphoma
• Hepatosplenic T-cell lymphoma
• Subcutaneous panniculitis-like T-cell lymphoma
• Primary cutaneous gamma-delta T-cell lymphoma
• Primary cutaneous CD8+ aggressive epidermotropic lymphoma
• Primary cutaneous CD4+ small/medium T-cell lymphoma

4. Active malignancy other than the one treated in this research. Prior history ofmalignancies unless the patient has been free of the disease for ≥ 2 years. However,patients with the following history are allowed:
5. Basal or squamous cell carcinoma of the skin
6. Carcinoma in situ of the cervix
7. Carcinoma in situ of the breast
8. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor,nodes, metastasis clinical staging system
9. Vaccinated with live, attenuated vaccines within 6 months of enrollment
10. Use of any standard or experimental anti-cancer drug therapy before the start oftreatment except COP (cyclophosphamide, vincristine, prednisone) in case of (or highrisk of tumor lysis syndrome) or etoposide for a maximum of 3 doses (at a maximum doseof 150mg/m2) for HLH (Hemophagocytic Lymphohistiocytosis).
11. A corticosteroids therapy > 1mg/kg lasting more than 14 days prior to Cycle 1 Day 1
12. Positive serology for Human Immunodeficiency Virus (HIV) and Human T-LymphotrophicVirus (HTLV1)
13. Active Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections defined as:

• HBV :
• HBs Ag positive
• HBs Ag negative, anti-HBs antibody positive and anti-HBc antibody positive withdetectable viral DNA
• HCV : Anti-VHC antibody positive with detectable viral RNA 9. Pregnant, planning to becomepregnant or lactating WOCBP 10. Any significant medical conditions, laboratory abnormalityor psychiatric illness likely to interfere with the participation in this clinical study (according to the investigator's decision) 11. Person deprived of his/her liberty by ajudicial or administrative decision 12. Person hospitalized without consent 13. Adultperson under legal protection